🔗 Share this article

While the US proceeds with sweeping adjustments to its immunization schedules, an unexpected name appears somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by casting doubt on coronavirus shots during the global health crisis and has concentrated on possible deaths after COVID-19 immunization in her recent tenure at the Food and Drug Administration.

Proposed Changes to Pediatric Vaccine Schedule

Public health authorities were set to announce sweeping changes to the pediatric immunization program recently, aligning the US with Denmark’s vaccine program, sources say – a major change that would put the US at odds with much of the global community with no evidence for benefit. The announcement has been postponed until the new year.

In place of Vinay Prasad, Dr. Høeg is scheduled to present at the meeting. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to lead the office this year.

A New Direction at the Agency

The acting appointment may indicate a closer partnership between the pharmaceutical and biologics branches as Dr. Høeg and Prasad solidify control at the regulatory agency – and it suggests a renewed priority upon rolling back long-standing vaccines at the FDA.

The new acting director has frequently advocated for ending some pediatric vaccine recommendations in the US so as to align more like the Danish model, a society with nationalized medicine and a population roughly the size of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on vaccination policy – traditionally the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Questions Over Background

Dr. Høeg has no obvious experience in pharmaceutical research, oversight or administrative roles, which has been customary for past heads of the biologics center. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“It seems she lacks to have the requisite experience” for overseeing the pharmaceutical oversight division, said Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a major agency. She is not an expert in industry regulation.”

Previous directors of the center would “understand laws and regulations and the underlying principles of drug development”, commented Dr. Janet Woodcock. “Frankly, she lacks the type of experience that prior appointees who ran the center have had.”

The drug center has an vast workload at the FDA, the former commissioner pointed out.

“The public just zeroes in on the innovative therapies, but the off-patent medication office authorizes thousands of off-brand pharmaceuticals. There’s a biosimilars program, non-prescription drug unit and more, and every single one need to be looked after,” she explained. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a substantial management aspect to the position, which oversees more than 5,000 employees. “It is a huge administrative position, if you execute it properly,” Woodcock concluded.

Response and Contentious Initiatives

In response to concerns about Dr. Høeg's fitness for the role and whether this selection signifies greater collaboration among regulatory chiefs on vaccines, a press secretary responded that the “inquiries rely on inaccurate premises”.

“Her experience matches the duties of her position,” the representative said, noting the period Dr. Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

As acting director, Høeg inherits the agency head's controversial fast-track approval initiative, a disputed one-day medication authorization process that reportedly worried her predecessors. “How are these medications being picked for this voucher program? Who takes the decisions?” Howard questioned. “There is a lot of secrecy happening at the regulatory body right now.”

Broadly speaking, he stated, “the FDA appears to be shifting towards less stringent rules of all drugs, aside from vaccines.”

Public History on Vaccines

With vaccines, Dr. Høeg has a more documented, if problematic, history, some experts have noted. She authored a research paper using non-validated public submissions to estimate the frequency of heart inflammation after Covid immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccinations are more dangerous than they are.

Included in her “desired changes” for the incoming federal leadership encompassed revising regulations for novel immunizations and ending “unnecessary” vaccines, she said post-election on a online show. At the FDA, Dr. Høeg has according to sources suggested barring adolescent males from getting Covid vaccines.

“She is an thorough true believer who starts off with her preconceived notions and works backwards to fit the data in a very disingenuous, fraudulent way,” Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg became part of fellow dissenters, {like|